Numerai GP LLC Buys Shares of 18,668 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Numerai GP LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,668 shares of the company's stock, valued at approximately $1,034,000.

Several other hedge funds also recently made changes to their positions in the business. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $25,000. R Squared Ltd purchased a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth approximately $53,000. Quarry LP purchased a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $166,000. HighTower Advisors LLC purchased a new position in Tarsus Pharmaceuticals in the fourth quarter worth $207,000. Finally, Summit Investment Advisors Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after buying an additional 244 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, General Counsel Bryan Wahl sold 3,341 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the sale, the general counsel now owns 58,057 shares in the company, valued at $2,687,458.53. This trade represents a 5.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bobak R. Azamian sold 7,131 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $330,093.99. Following the transaction, the chief executive officer now owns 70,720 shares in the company, valued at approximately $3,273,628.80. This represents a 9.16% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,542 shares of company stock worth $1,581,173. Company insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Trading Down 0.6%

NASDAQ TARS traded down $0.27 during trading on Tuesday, hitting $44.74. The company had a trading volume of 109,242 shares, compared to its average volume of 697,438. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -11.72 and a beta of 0.94. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The company's fifty day moving average is $48.01 and its 200-day moving average is $49.22.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. On average, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analysts Set New Price Targets

TARS has been the topic of a number of research reports. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Guggenheim raised their price target on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. The Goldman Sachs Group lifted their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. Finally, Barclays dropped their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $66.33.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.